Stockscreener 앱 받기
80.00
1.45%
1.14
시간 외 거래:
81.58
1.58
+1.97%
전일 마감가:
$78.86
열려 있는:
$80
하루 거래량:
727.76K
Relative Volume:
0.76
시가총액:
$3.46B
수익:
$2.04M
순이익/손실:
$-162.34M
주가수익비율:
-19.45
EPS:
-4.1129
순현금흐름:
$-129.27M
1주 성능:
-0.40%
1개월 성능:
+60.90%
6개월 성능:
+117.69%
1년 성능:
+288.54%
1일 변동 폭
$77.48
$81.21
1주일 범위
$76.22
$82.27
52주 변동 폭
$13.37
$88.02
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
80.00 | 3.41B | 2.04M | -162.34M | -129.27M | -4.1129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | 개시 | Truist | Buy |
| 2025-07-02 | 개시 | William Blair | Outperform |
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Wells Fargo & Company Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Wells Fargo Initiates Dianthus Therapeutics at Overweight - marketscreener.com
Wells Fargo reiterates Dianthus Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP - Insider Monkey
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - AOL.com
Biotech shares soar by 288% following a major funding round, with an early investor disclosing a $14 million cash-out - Bitget
Dianthus Therapeutics, Inc. (DNTH) stock jumps 12.0%: Will it continue to soar? - MSN
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Top 5 Boring Stocks That Make Money - Insider Monkey
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity - Stock Titan
Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) - MSN
William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026 - Meyka
Dianthus Therapeutics closes $719M public offering - Investing.com Nigeria
HighVista Strategies Boosts Stake in Dianthus Therapeutics - National Today
HighVista Strategies LLC Buys 38,364 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. $DNTH is Fairmount Funds Management LLC's Largest Position - MarketBeat
Boothbay Fund Management Buys Stake in Dianthus Therapeutics - National Today
Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (DNTH) Is Up 19.4% After Early CAPTIVATE GO Decision And $719M Raise - simplywall.st
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm - MarketBeat
Braidwell LP Purchases Shares of 835,057 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple - Sahm
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics - National Today
Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus therapeutics CAO sells shares for $3.56 million - Investing.com Nigeria
Dianthus Therapeutics EVP Sells $2.76M in Stock - National Today
Dianthus therapeutics CAO sells shares for $3.56 million By Investing.com - Investing.com Australia
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock - MarketBeat
Dianthus therapeutics CEO Garcia sells $10m in shares - Investing.com
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million By Investing.com - Investing.com Nigeria
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million - Investing.com
Dianthus Therapeutics Executives Sell Off Significant Shares - TradingView
Dianthus Therapeutics closes $719M public offering By Investing.com - Investing.com Australia
Dianthus Therapeutics Announces Major Public Equity Offering - The Globe and Mail
Dianthus Therapeutics stock surges 25% on positive trial data - Investing.com Nigeria
Dianthus (DNTH) CAO cashes out 43,682 shares after option exercises - Stock Titan
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Bitget
Biotech Dianthus raises $719M to push autoimmune disease drugs - Stock Titan
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million - TradingView
Dianthus (NASDAQ: DNTH) raises $673.5M in stock and warrant deal - Stock Titan
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Midtown drug company to sell up to $625M in stock to fund autoimmune research - Crain's New York
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Dianthus Therapeutics (DNTH) offers 7.31M shares, $624.9M gross - Stock Titan
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):